{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,20]],"date-time":"2026-02-20T00:12:43Z","timestamp":1771546363110,"version":"3.50.1"},"reference-count":20,"publisher":"Georg Thieme Verlag KG","issue":"02","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Z Gastroenterol"],"published-print":{"date-parts":[[2026,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Intraepithelial lymphocytosis is a hallmark of microscopic colitis commonly presenting with debilitating chronic watery diarrhea. The exact pathophysiology remains unclear but is believed to involve an abnormal immune response to the luminal microenvironment in genetically predisposed individuals. Medications like nonsteroidal anti-inflammatory drugs, proton pump inhibitors, and antidepressants, as well as alcohol consumption and smoking have been regarded as risk factors for microscopic colitis. Lymphocytic colitis often responds well to anti-inflammatory treatment, with budesonide being a first line therapy. Relapse is common after discontinuing budesonide, often necessitating low-dose maintenance therapy. Advanced therapies including anti-TNF-alpha (e.g. infliximab) or anti-integrin (e.g. vedolizumab) agents as well as JAK inhibitors (e.g. upadacitinib) may be considered in refractory cases. However, confirmation of the diagnosis and ruling out other etiologies are necessary before intensifying treatment. Here, we present the case of a 78-year-old female patient with a twenty month history of chronic refractory diarrhea, repeatedly diagnosed as microscopic lymphocytic colitis. Following further deterioration and the development of hepatosplenomegaly with atypical liver lesions, a review of colonic biopsies and additional work-up led to the correct diagnosis.<\/jats:p>","DOI":"10.1055\/a-2722-1140","type":"journal-article","created":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T00:47:38Z","timestamp":1767919658000},"page":"179-183","source":"Crossref","is-referenced-by-count":0,"title":["Chronic Watery Diarrhea With Colonic Intraepithelial Lymphocytosis Refractory To Budesonide Treatment \u2013 A Case Report"],"prefix":"10.1055","volume":"64","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0096-7903","authenticated-orcid":false,"given":"Markus","family":"Reiser","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine and Gastroenterology, Knappschaft Kliniken GmbH, Marl, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Benita","family":"Pawlak","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine and Gastroenterology, Knappschaft Kliniken GmbH, Marl, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Frank","family":"Oehmen","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine and Gastroenterology, Knappschaft Kliniken GmbH, Marl, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Edin","family":"Zahirovic","sequence":"additional","affiliation":[{"name":"Department of Pathology Recklinghausen, Recklinghausen, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Klaus J","family":"Schmitz","sequence":"additional","affiliation":[{"name":"Department of Pathology Recklinghausen, Recklinghausen, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"194","published-online":{"date-parts":[[2026,1,8]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1016\/j.cgh.2024.08.026","article-title":"Update on the Epidemiology and Management of Microscopic Colitis","volume":"23","author":"AF Peery","year":"2025","journal-title":"Clin Gastroenterol Hepatol"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"1795","DOI":"10.1053\/j.gastro.2018.08.042","article-title":"Efficacy and Safety of Budesonide, vs Mesalazine or Placebo, as Induction Therapy for Lymphocytic Colitis","volume":"155","author":"S Miehlke","year":"2018","journal-title":"Gastroenterology"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1111\/j.1440-1746.2006.04511.x","article-title":"Mesalazine with or without cholestyramine in the treatment of microscopic colitis: Randomized controlled trial","volume":"22","author":"C Calabrese","year":"2007","journal-title":"J Gastroenterol Hepatol"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1097\/mcg.0000000000001914","article-title":"Efficacy and Safety of Vedolizumab and Tumor Necrosis Factor Inhibitors in the Treatment of Steroid-refractory Microscopic Colitis","volume":"58","author":"NEH Chehade","year":"2023","journal-title":"J Clin Gastroenterol"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"1000","DOI":"10.1097\/meg.0000000000002409","article-title":"Efficacy and safety of biologic therapy in microscopic colitis: systematic review and meta-analysis","volume":"34","author":"V Taneja","year":"2022","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.14309\/crj.0000000000000979","article-title":"Medically Refractory Lymphocytic Colitis Successfully Treated With Upadacitinib","volume":"10","author":"Y Miyatani","year":"2023","journal-title":"ACG Case Rep J"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"1352","DOI":"10.1093\/ibd\/izad085","article-title":"Upadacitinib as a Novel Treatment in Therapy Refractory Collagenous Colitis","volume":"29","author":"L Boneschansker","year":"2023","journal-title":"Inflamm Bowel Dis"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1002\/ajh.23213","article-title":"Type II enteropathy\u2010associated T\u2010cell lymphoma: A multicenter analysis from the Asia Lymphoma Study Group","volume":"87","author":"E Tse","year":"2012","journal-title":"Am J Hematol"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1007\/s12328-021-01417-3","article-title":"Small bowel T-cell lymphoma: a MEITL-ing diagnosis","volume":"14","author":"S Mago","year":"2021","journal-title":"Clin J Gastroenterol"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"2541","DOI":"10.1007\/s00277-019-03791-y","article-title":"Multicenter retrospective analysis of the clinicopathologic features of monomorphic epitheliotropic intestinal T-cell lymphoma","volume":"98","author":"JH Yi","year":"2019","journal-title":"Ann Hematol"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"1898","DOI":"10.1182\/blood.2023021788","article-title":"Current and upcoming treatment approaches to uncommon subtypes of PTCL (EATL, MEITL, SPTCL, and HSTCL)","volume":"144","author":"E Marchi","year":"2024","journal-title":"Blood"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2024.1388623","article-title":"Hematopoietic stem cell transplantation to improve prognosis in aggressive monomorphic epitheliotropic intestinal T-cell lymphoma","volume":"14","author":"G-J Min","year":"2024","journal-title":"Front Oncol"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"3418","DOI":"10.1182\/blood-2010-02-270785","article-title":"Treatment and prognosis of mature T-cell and NK-cell lymphoma: an analysis of patients with T-cell lymphoma treated in studies of the German High-Grade Non-Hodgkin Lymphoma Study Group","volume":"116","author":"N Schmitz","year":"2010","journal-title":"Blood"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1080\/10245332.2017.1335979","article-title":"Positron emission tomography computed tomography features of monomorphic epitheliotropic intestinal T-cell lymphoma","volume":"23","author":"TSY Chan","year":"2018","journal-title":"Hematology"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1097\/md.0000000000031326","article-title":"Pegylated liposomal doxorubicin (PLD)-containing regimen as a novel treatment of monomorphic epithelial intestinal T-cell lymphoma (MEITL): A case report and review of literature","volume":"101","author":"Y Chen","year":"2022","journal-title":"Medicine"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.1634\/theoncologist.2015-0043","article-title":"Romidepsin for the Treatment of Peripheral T\u2010Cell Lymphoma","volume":"20","author":"SP Iyer","year":"2015","journal-title":"Oncol"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"8507","DOI":"10.1200\/jco.2013.31.15_suppl.8507","article-title":"Belinostat, a novel pan-histone deacetylase inhibitor (HDACi), in relapsed or refractory peripheral T-cell lymphoma (R\/R PTCL): Results from the BELIEF trial","volume":"31","author":"OA O\u2019Connor","year":"2013","journal-title":"J Clin Oncol"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"1182","DOI":"10.1200\/jco.2010.29.9024","article-title":"Pralatrexate in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma: Results From the Pivotal PROPEL Study","volume":"29","author":"OA O\u2019Connor","year":"2011","journal-title":"J Clin Oncol"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1016\/s0140-6736(18)32984-2","article-title":"Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial","volume":"393","author":"S Horwitz","year":"2019","journal-title":"Lancet"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1177\/2058738419829387","article-title":"Monomorphic epitheliotropic intestinal T-cell lymphoma may mimic intestinal inflammatory disorders","volume":"33","author":"S Tian","year":"2019","journal-title":"Int J Immunopathol Pharmacol"}],"container-title":["Zeitschrift f\u00fcr Gastroenterologie"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/a-2722-1140.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T23:45:08Z","timestamp":1771544708000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/a-2722-1140"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,8]]},"references-count":20,"journal-issue":{"issue":"02","published-online":{"date-parts":[[2026,2,19]]},"published-print":{"date-parts":[[2026,2]]}},"URL":"https:\/\/doi.org\/10.1055\/a-2722-1140","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["0044-2771","1439-7803"],"issn-type":[{"value":"0044-2771","type":"print"},{"value":"1439-7803","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,8]]}}}